Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins

• Published in: Frontiers in cellular and infection microbiology 2022-07, Vol.12, p.967493-967493
• Main Authors: Chen, Jing, Xu, Wang, Li, Letian, Yi, Lichao, Jiang, Yuhang, Hao, Pengfei, Xu, Zhiqiang, Zou, Wancheng, Li, Peiheng, Gao, Zihan, Tian, Mingyao, Jin, Ningyi, Ren, Linzhu, Li, Chang
• Format: Article
• Language: English
• Subjects: Cellular and Infection Microbiology; chimeric; Coronavirus Disease 2019 (COVID-19); severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2); spike; virus-like particle (VLP)
• ISSN: 2235-2988; 2235-2988
• DOI: 10.3389/fcimb.2022.967493

Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has posed a constant threat to human beings and the world economy for more than two years. Vaccination is the first choice to control and prevent the pandemic. However, an effective SARS-CoV-2 vaccine against the virus infection is still needed. This study designed and prepared four kinds of virus-like particles (VLPs) using an insect expression system. Two constructs encoded wild-type SARS-CoV-2 spike (S) fused with or without H5N1 matrix 1 (M1) (S and SM). The other two constructs contained a codon-optimized spike gene and/or M1 gene (mS and mSM) based on protein expression, stability, and ADE avoidance. The results showed that the VLP-based vaccine could induce high SARS-CoV-2 specific antibodies in mice, including specific IgG, IgG1, and IgG2a. Moreover, the mSM group has the most robust ability to stimulate humoral immunity and cellular immunity than the other VLPs, suggesting the mSM is the best immunogen. Further studies showed that the mSM combined with Al/CpG adjuvant could stimulate animals to produce sustained high-level antibodies and establish an effective protective barrier to protect mice from challenges with mouse-adapted strain. The vaccine based on mSM and Al/CpG adjuvant is a promising candidate vaccine to prevent the COVID-19 pandemic.